Get the latest news on melanoma


6/23/2022

Study identifies unique underlying molecular factors driving melanoma development

6/22/2022

ASCO 2022: An abundance of data for the field of melanoma

6/20/2022

T-VEC plus Pembrolizumab generates promising responses, safety in PD-1–refractory advanced melanoma

6/17/2022

Recommended phase 2 dose of tebentafusp shows promise in metastatic uveal melanoma

6/17/2022

Toripalimab with axitinib active in treatment-naive advanced mucosal melanoma

6/17/2022

Omitting node dissection, adjuvant therapy may be safe for some with Stage III melanoma

6/16/2022

Androgen receptor signaling may contribute to targeted therapy resistance in patients with melanoma

6/16/2022

Quavonlimab/pembrolizumab combo shows modest antitumor activity in advanced melanoma

6/15/2022

Androgen receptor signaling contributes to targeted therapy resistance in melanoma

6/13/2022

What is desmoplastic melanoma?

6/7/2022

Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma

6/7/2022

Georgina V. Long, MD, PhD, on Melanoma: new data on pembrolizumab, dabrafenib, and trametinib

6/7/2022

Georgina V. Long, MD, PhD, on Melanoma: distant metastasis–free survival with adjuvant pembrolizumab

6/7/2022

PDS0101 shows synergistic activity with pembrolizumab in HPV16+ head and neck squamous cell carcinoma

6/7/2022

War against NRAS-mutant melanoma using targeted therapies remains challenging

6/7/2022

Concurrent therapy improves responses, increases toxicity in stage III melanoma

6/6/2022

Nivolumab plus relatlimab demonstrates sustained PFS benefit in advanced melanoma

6/2/2022

Basics of melanoma diagnosis

5/25/2022

Approaches to Potentiate Immune Response in patients who do not respond to Anti–PD-1 therapy for melanoma

5/25/2022

SkylineDx announces Medicare coverage for its predictive melanoma assay Merlin™ test

5/24/2022

Necroptosis-associated classification combined with tumor microenvironment characteristic analysis of cutaneous melanoma

5/24/2022

USP35 is a potential immunosuppressive factor in skin cutaneous melanoma

5/23/2022

A decade of transformation in melanoma treatments

5/20/2022

Merck receives positive EU CHMP opinion for KEYTRUDA® (pembrolizumab) as adjuvant treatment for adult and adolescent (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection

5/18/2022

Dr Jeffrey Weber on the staging of melanoma and choosing treatment options

5/18/2022

BIO Biotech announces initiation of phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma

5/15/2022

Apatinib prompts eesponses in patients with recurrent melanoma

5/13/2022

Sotigalimab plus nivolumab shows encouraging activity in Anti–PD-1 refractory melanoma

5/10/2022

T-Cell behavior influences which tumors respond to immunotherapy

5/8/2022

Morphology drives melanoma risk

5/3/2022

Hot topic: a prognostic liquid biopsy for use with uveal melanoma is predictive of metastasis

4/26/2022

Administration of RP1 through intratumoral injection offers unique advantages in melanoma treatment

4/25/2022

RELATIVITY-047 update: novel immunotherapy duo delays disease progression in advanced melanoma

4/24/2022

Soluble microenvironment appears to impact how melanoma cells interact with immune cells

4/23/2022

Sotigalimab/Pembrolizumab jumpstarts immune activity, ignites clinical responses in metastatic melanoma

4/22/2022

DNA mismatch repair proteins may predict ICI response in cutaneous melanoma

4/21/2022

Combo of BO-112 and pembrolizumab elicits response in advanced melanoma

4/19/2022

Study probes immune context differences in BRAF-Mutant, wild-type melanoma

4/15/2022

Non-Hodgkin’s Lymphoma and melanoma: is there a connection?

4/14/2022

Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1

4/13/2022

Delays in BRAF test results affect quality of care, therapeutic options in melanoma

4/13/2022

Sotigalimab plus Pembrolizumab demonstrates favorable safety profile in metastatic melanoma

4/13/2022

Primary Care Screening for Skin Cancer Appears to Boost Early Detection

4/12/2022

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma

4/9/2022

Epidemiology and outcomes of gastrointestinal mucosal melanomas: a national database analysis

4/8/2022

Nivolumab with PD-L1/IDO peptide vaccine shows efficacy in metastatic melanoma

4/8/2022

ADAPT-IT raises question about 4-dose schedule of nivo/iIpi in patients with metastatic melanoma

4/7/2022

Primary Care-Based Melanoma Screening Linked to Higher Incidence of Thin Melanoma

4/6/2022

RP1/Nivolumab combo produces deep, durable responses in melanoma and other skin cancers

4/5/2022

Global melanoma incidence high and on the rise

3/18/2022

Tebentafusp Shows Significant OS Benefit in Advanced Uveal Melanoma

3/18/2022

Melanin-targeted PET probe tracks down malignant melanoma lesion

3/18/2022

Bristol Myers’ Opdivo combo Opdualag scores FDA approval in melanoma, opens 3rd immune checkpoint drug class

3/17/2022

Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN(R)-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC) | BioSpace

3/17/2022

FDA grants fast track status to 7HP349 for PD-1–resistant metastatic melanoma

3/16/2022

The sentinel lymph node is most important prognostic factor for melanoma, study finds

3/15/2022

Relatlimab/Nivolumab Combo Continues to Impress in Previously Untreated Metastatic or Unresectable Melanoma

3/14/2022

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors

3/14/2022

Bristol Myers Squibb and Nektar announce update on phase 3 PIVOT IO-001 trial evaluating Bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma

3/13/2022

Researchers uncover immune environment of rare type of melanoma

3/2/2022

Study explores signature gut microbiome connection with immune checkpoint inhibitor response in advanced melanomas

3/1/2022

Referral centers worldwide adopt systemic therapies, reduce lymph node removal surgeries

2/28/2022

Discovering a potential explanation for treatment resistance in skin cancer

2/24/2022

Lack of guidelines create need for novel options for vulvar/vaginal melanoma

2/23/2022

Nurse-led program demonstrates initial success in reducing severe immune-related toxicity in melanoma

2/21/2022

Amelanotic malignant mucosal melanoma of the nasal cavity: case report and literature review

2/18/2022

The value of a high-fiber diet for melanoma patients on immunotherapy

2/17/2022

Study finds early signs of response to immunotherapy for melanoma in blood

2/17/2022

Vitiligo from checkpoint inhibitors not limited to melanoma

2/16/2022

Hillstream BioPharma receives orphan drug designation for HSB-1216 for the treatment of uveal melanoma

2/15/2022

Potential use of FDG-PET findings in reducing duration of immunotherapy in patients with advanced melanoma

2/14/2022

Acral lentiginous melanoma survival varies by race, SES

2/14/2022

Creating a promising pathway for faster access to new drugs — and a Califf confirmation

2/14/2022

Newly approved tebentafusp requires up-front active toxicity management in melanoma

2/9/2022

Personalized medicine approaches continue to gain steam in BRAF/NRAS+ metastatic melanoma

2/8/2022

New data shed light on treatment sequencing in melanoma

2/7/2022

NeoImmuneTech announces first patient dosed in phase 2 study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in high-risk skin cancers

2/7/2022

Melanoma thickness associated with decreased survival

2/6/2022

Growing therapy approaches for BRAF-mutant advanced melanoma

2/4/2022

FDA follow-up: Utilizing tebentafusp in clinical practice for metastatic uveal melanoma

2/3/2022

Castle biosciences collaborates with the National Cancer Institute to link DecisionDx®-Melanoma testing data with SEER registries’ cutaneous melanoma cases

1/29/2022

Prior therapy may reduce efficacy of tumor-infiltrating lymphocytes for advanced melanoma

1/28/2022

Expert explains significance of LAG-3 inhibition in novel immunotherapies for melanoma

1/26/2022

FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma

1/26/2022

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology

1/26/2022

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

1/24/2022

Darovasertib/crizotinib combo achieves promising responses in pretreated metastatic uveal melanoma

1/19/2022

Expert explains rationale behind RELATIVITY-047 in melanoma

1/18/2022

Evaxion Biotech receives regulatory clearance to initiate phase 2 trial of EVX-01 in combination with KEYTRUDA® for treatment of melanoma

1/18/2022

Evaxion Biotech receives regulatory clearance to initiate phase 2 trial of EVX-01 in combination with KEYTRUDA® for treatment of melanoma

1/17/2022

Newcastle University scientists develop new test to identify melanoma risk

1/14/2022

New, updated data demonstrate promising future in advanced melanoma

1/14/2022

Pioneering test predicts return of malignant melanoma

1/12/2022

Data published in Ocular Oncology and Pathology demonstrates highly accurate performance of DecisionDx®-UMSeq for patients with uveal melanoma

1/11/2022

Study: Relatlimab, nivolumab improve progression-free survival in metastatic melanoma

1/10/2022

Melanoma patient on immunotherapy develops severe dermatitis

1/7/2022

Cutaneous adverse events may be linked to clinical benefit in metastatic melanoma

1/6/2022

Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma

1/5/2022

Pembrolizumab after resection of stage II melanoma reduces recurrence risk

1/4/2022

Inhibrx announces initial phase 1 dose escalation results for INBRX-106, a novel hexavalent OX40 agonist, in combination with Keytruda® (pembrolizumab) for NSCLC and melanoma patients

1/3/2022

First-line nivolumab/ipilimumab yields durable survival benefit in asymptomatic melanoma with brain mets

1/3/2022

Prognostic biomarkers of cutaneous melanoma

12/28/2021

Nivolumab plus ipilimumab benefits patients with asymptomatic melanoma brain metastases

12/23/2021

Dietary fiber improves outcomes for melanoma patients on immunotherapy, research shows

12/22/2021

Melanoma update: 3 important trials from ESMO 2021

12/21/2021

Chromosome-level changes underlying melanoma drug resistance uncovered

12/17/2021

BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

12/16/2021

Nivolumab and ipilimumab combination bests monotherapy in improving clinical outcomes in advanced melanoma

12/15/2021

Dr. Weber discusses unmet needs in ocular and mucosal melanoma

12/10/2021

FDA approves FoundationOne CDx as companion diagnostic for melanoma

12/10/2021

Darovasertib/crizotinib shows early efficacy in metastatic uveal melanoma

12/9/2021

Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody

12/7/2021

IDEAYA reports clinical data from Phase 2 expansion dose of darovasertib and crizotinib synthetic lethal combination in heavily pre-treated metastatic uveal melanoma

12/6/2021

The U.S. Food and Drug Administration has approved the use of Merck’s Keytruda for the adjuvant treatment of persons diagnosed with stage IIB or IIC melanoma following complete resection.

12/3/2021

FDA approves Merck’s KEYTRUDA® (pembrolizumab) as adjuvant treatment for adult and pediatric (≥12 years of age) patients with Stage IIB or IIC melanoma following complete resection

12/1/2021

Dr. Luke on toxicities with targeted therapy vs immunotherapy in melanoma

12/1/2021

BO-112 plus pembrolizumab improves ORR in advanced melanoma after progression on Anti–PD-1 therapy

12/1/2021

A Phase II study of CMP-001 and nivolumab in people with advanced melanoma that persists despite immunotherapy

11/26/2021

Expansion of IOA-244 trial fully enrolled for uveal melanoma

11/26/2021

A new mechanism involved in early melanoma metastasis

11/23/2021

Huntsman Cancer Institute researchers uncover insights into how moles change into melanoma

11/23/2021

FDA grants fast track designation to BNT111 for advanced melanoma

11/19/2021

West Virginia University gets FDA approval for clinical trial of drug to treat eye cancer ‘from the inside out’

11/19/2021

Nivolumab, ipilimumab combination therapy improves overall survival for patients with melanoma, brain metastases

11/19/2021

BioNTech’s skin cancer therapy wins FDA’s fast track designation

11/19/2021

TCR T-cell therapy induces response in solid cancers

11/19/2021

Long-term radiation therapy-related risk of second primary malignancies in patients with lung cancer

11/15/2021

Immunotherapy first wins in advanced BRAF-positive melanoma—DREAMseq shows 20% absolute improvement in 2-year survival with nivolumab-ipilimumab upfront

11/12/2021

Highlight Therapeutics, announced positive preliminary results of a Phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma whose disease had progressed on first-line anti-PD1-based therapy.

11/10/2021

MediciNova announces new data regarding MN-166 (ibudilast) in uveal melanoma presented at the CURE OM Global Science Meeting

11/9/2021

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

11/9/2021

Modulation Therapeutics obtains FDA investigational new drug application approval to trial its drug, MTI-201, to treat uveal melanoma.

11/8/2021

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it has fully enrolled the metastatic uveal melanoma expansion cohort of the DIONE-01 study evaluating iOnctura’s lead compound, the selective PI3Kδ inhibitor IOA-244

11/3/2021

UV1, a universal cancer vaccine, has received fast track designation from the FDA for the use in unresectable or metastatic melanoma.

11/3/2021

The FDA has accepted Memgen’s investigational new drug (IND) application for MEM-288, the company’s immunotherapy candidate for the treatment of multiple solid tumors

11/3/2021

Researchers work towards national melanoma screening program using 3D patient avatar technology

10/31/2021

KEYTRUDA continued to improve Recurrence-Free Survival (RFS) compared to placebo as adjuvant therapy for patients with resected stage IIB or IIC melanoma at 2nd interim analysis of phase 3 KEYNOTE-716 trial

10/30/2021

Scientists develop new approach to combat treatment-resistant melanoma

10/27/2021

New study from researchers at the Perelman School of Medicine at the University of Pennsylvania uses melanoma models in mice to show that drugs that target androgen receptors (AR) in prostate cancer can be effectively repurposed to block ZIP9 and thereby inhibit melanoma in men

10/26/2021

An expert in melanoma cancer treatment examines monitoring patients with melanoma using ctDNA.

10/25/2021

FDA grants fast track designation to UV1 for advanced melanoma

10/25/2021

Evaxion Biotech announces clinical collaboration to evaluate lead product candidate with KEYTRUDA® (pembrolizumab) in patients with melanoma

10/24/2021

Study reveals temporal, anatomic complexity in genetic evolution of uveal melanoma

10/22/2021

Neoadjuvant talimogene laherparepvec (T-VEC) followed by surgery significantly improved survival when compared with surgery alone in patients with advanced, resectable melanoma

10/21/2021

Ultimovacs receives dual FDA Fast Track Designation for UV1 in advanced malignant melanoma

10/20/2021

A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity

10/20/2021

Yale Cancer Center study shows new strategy to boost immune system to fight melanoma

10/19/2021

Defence therapeutics scores again with new planned phase 1 trial evaluating its DC cancer vaccine candidate AccuVAC-D002 against melanoma

10/18/2021

ctDNA reduction after tebentafusp predicts OS in uveal melanoma

10/9/2021

Axitinib plus anti-PD1 regimen is effective as first-line mucosal melanoma treatment

10/8/2021

The European Medicines Agency validated the Marketing Authorization Application of the fixed-dose combination of Opdivo (nivolumab) and relatlimab

10/5/2021

Tebentafusp Yields Long-Lasting Overall Survival Benefit in HLA-A*02:01+ Patients With Metastatic Uveal Melanoma

10/5/2021

Guardant Health Begins Study of Reveal Liquid Biopsy Test to Predict Cancer Recurrence

10/4/2021

ctDNA Reduction Is Potentially Predictive of OS Vs RECIST in Metastatic Uveal Melanoma

10/1/2021

UK Researchers Show Cytotoxic T-Cell Level Predicts Melanoma Immunotherapy Response

9/29/2021

A subset of patients with metastatic uveal melanoma achieved promising responses after treatment with entinostat and pembrolizumab.

9/29/2021

Lithuanian Researchers Develop Novel Noninvasive Method for Diagnosing Melanoma That Has Greater than 90% Accuracy

9/24/2021

The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

9/24/2021

Researchers suggest that melanomas that metastasize to the adrenal gland are resistant to checkpoint inhibitors

9/23/2021

Eisai and Merck present first-time data from two studies evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) in seven different tumor types at ESMO Virtual Congress 2020

9/23/2021

Cedars-Sinai Cancer researchers have created a new system for classifying melanoma when the disease has spread to the lymph nodes.

9/23/2021

Alrizomadlin Granted FDA Fast Track Designation for Relapsed/Refractory Unresectable or Metastatic Melanoma

9/22/2021

A phase I study is recruiting patients with uveal melanoma to investigate the highest dose of FHD-286 to prevent tumor growth

9/21/2021

DermTech announced that the results of its TRUST (LINC00518) study

9/20/2021

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

9/19/2021

ctDNA Improved Predictor of Survival for Previously Treated Metastatic Uveal Melanoma

9/18/2021

Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma [ESMO Congress 2021 Press Release]

9/15/2021

BioNTech wins FDA’s orphan drug status for melanoma candidate

9/13/2021

Instil Bio to Begin Phase II Trial of TIL Therapy for Advanced Melanoma

9/12/2021

Factors of Ipilimumab/Nivolumab Success in Metastatic Melanoma Identified

9/9/2021

OncoBeta initiates international EPIC-Skin study with Rhenium-SCT® for the treatment of melanoma skin cancer

9/9/2021

Promising treatments for some rare forms of melanoma may be on the horizon

9/9/2021

Karyopharm Therapeutics Inc is recruiting patients for a study investigating selinexor in combination with pembrolizumab for the treatment of locally advanced or metastatic melanoma

9/8/2021

Similar Therapy Tolerance Seen Among Patients With Melanoma, Regardless of Age

9/7/2021

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

9/4/2021

Primary sites of uveal melanoma associated with distinct survival outcomes and clinicopathological features: A SEER population-based study of 4359 cases

8/30/2021

Clinical trial suggests new combination treatment could prolong survival in uveal melanoma

8/27/2021

Gut bacteria linked to immunotherapy response, toxicity in melanoma patients

8/25/2021

FDA grants priority review to tebentafusp for uveal melanoma treatment

8/25/2021

FDA accepts biologics license application for tebentafusp in metastatic uveal melanoma

8/24/2021

Tebentafusp Gets Priority Review for Metastatic Uveal Melanoma

8/24/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

8/22/2021

Researchers assess immune checkpoint inhibitor resistance in melanoma treatment

8/20/2021

New melanoma treatment called TIL therapy uses patient’s own immune system to fight their cancer

8/20/2021

Prognostic Value of Tumor-Infiltrating Lymphocytes in Sinonasal Mucosal Melanoma

8/19/2021

Anuric Kidney Failure in a Patient With Metastatic Melanoma

8/13/2021

Positive results observed with UV1 cancer vaccine plus pembrolizumab in metastatic melanoma

8/8/2021

Unusual presentation of giant upper limb malignant melanoma

8/6/2021

Study identifies source of DNA mutations that underlie melanoma

8/5/2021

Trial offers hope for patients with late-stage melanoma

8/5/2021

Dr. Jeffrey Weber relays melanoma updates from the 2021 ASCO Annual Meeting

8/5/2021

Merck’s Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers

8/5/2021

Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial

8/2/2021

FDA grants Fast Track Designation to nemvaleukin alfa for mucosal melanoma

7/30/2021

Study reveals source of DNA mutations in melanoma

7/28/2021

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

7/26/2021

Bempegaldesleukin plus nivolumab elicits responses in treatment-naïve, advanced melanoma

7/23/2021

FDA grants Orphan Drug Designation to alrizomadlin for stage IB-IV melanoma

7/23/2021

Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies

7/22/2021

Some antibiotics appear to be effective against melanoma, according to new research study on patient-derived tumors in mice

7/18/2021

Recent study shows that combining BRAF oncogene inhibitors and chemotherapy is an effective strategy for fighting metastatic melanoma

7/17/2021

Dr. Sunandana Chandra discusses emerging therapies in melanoma

7/16/2021

Study suggests which melanoma patients may avoid sentinel node biopsy

7/14/2021

BEMPEG plus nivolumab achieved “deep and durable” responses in previously untreated metastatic melanoma patients

7/12/2021

Combination of pembrolizumab and low-dose ipilimumab appeared to show significant antitumor activity among patients with advanced melanoma who previously failed immunotherapy

7/8/2021

Annual Report to the Nation: Rapid decrease in lung cancer and melanoma deaths lead overall continued decline in cancer death rate

7/7/2021

OncoSec, Merck enter agreement for late-stage metastatic melanoma combo

7/6/2021

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

7/2/2021

Liquid biopsy has potential to advance precision medicine in melanoma

6/29/2021

Cell-based immunotherapy shows promise against melanoma

6/28/2021

IDEAYA announces IDE397 Phase 1 clinical pharmacodynamic data and Phase 2 initiation of darovasertib and crizotinib combination

6/22/2021

Targovax receives Fast Track designation for ONCOS-102 in melanoma

6/21/2021

‘Suffocating’ cancer: a new headway in melanoma immunotherapy

6/18/2021

BioNTech announces first patient dosed in phase 2 clinical trial of mRNA-based BNT111 in patients with advanced melanoma

6/17/2021

Bergamottin, a natural furanocoumarin derived from grapefruits, is shown to induce DNA damage and inhibit malignant progression in melanoma by modulating miR-145/Cyclin D1 axis

6/17/2021

Novel brachytherapy device treats eye cancer with intensity-modulated radiation

6/16/2021

Minding Melanoma: Clinical trials

6/10/2021

Skyline Dx launches US prospective melanoma trial to validate Merlin Assay

6/10/2021

Old antidepressants show promise as immuno-oncology treatments in melanoma and colon cancer

6/9/2021

Stanford researchers have discovered that the level of certain proteins in the eye could predict survival risk in patients with uveal melanoma

6/8/2021

APG-115 plus pembrolizumab safe with preliminary efficacy in unresectable or metastatic melanoma or advanced solid tumors

6/7/2021

Melanoma outcomes are improved with nivolumab alone or with ipilimumab

6/7/2021

Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

6/6/2021

Lifileucel continues to show durable responses in advanced melanoma

6/6/2021

Combination of anti-LAG-3 antibody and nivolumab improves PFS in advanced melanoma

6/4/2021

Iovance Biotherapeutics announces clinical data for lifileucel in combination with pembrolizumab in advanced melanoma at ASCO 2021 annual meeting

6/4/2021

Alkermes results presented at ASCO 2021 show a dwindling response rate in melanoma patients receiving nemva monotherapy

6/4/2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

6/4/2021

Results presented at ASCO show a dwindling response rate in melanoma patients receiving Alkermes’ nemvaleukin monotherapy

6/3/2021

Multidisciplinary care of BRAF-mutant stage III melanoma: A physicians perspective review

5/30/2021

Vidutolimod/nivolumab under evaluation in PD-1-refractory advanced melanoma

5/28/2021

Combination therapy with nivolumab and relatimab prolongs progression-free survival in advanced melanoma

5/26/2021

A dual macrophage polarizer conjugate for synergistic melanoma therapy

5/19/2021

Dual immunotherapy regimen targeting novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma

5/19/2021

New Bristol Myers immunotherapy combo better than Opdivo alone in melanoma study

5/19/2021

Biomarker panels evaluated by multiplex immunoassays with high analytical performance demonstrated potential complementary values in detection of uveal melanoma

5/19/2021

6 ½ year outcomes for Opdivo in combination with Yervoy continue to demonstrate durable long-term survival benefits in patients with advanced melanoma

5/19/2021

Melanoma Research Foundation launches historic patient-reported ocular melanoma registry

5/19/2021

Study argues for the immediate treatment rather than observation of small uveal melanomas

5/12/2021

Genetic analysis of acral nevi and acral melanoma demonstrates different mutation patterns

5/11/2021

Tebentafusp shows promising results in large phase III clinical trial for metastatic uveal melanoma

5/7/2021

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders shows risk of flare

5/5/2021

Checkmate Pharmaceuticals announces initiation of patient dosing in potential registration trial of Vidutolimod in patients with anti-PD-1 refractory advanced melanoma

5/4/2021

Breakthrough immunotherapy drug tebentafusp cut the risk of dying by half in patients with metastasized ocular melanoma

5/4/2021

Castle Biosciences collaborates with the Colorado Melanoma Foundation and Epiphany Dermatology to provide free skin cancer screenings across the Southwest U.S.

5/3/2021

Aura Biosciences presents new preclinical AU-011 data in multiple tumor models of choroidal metastases and in choroidal melanoma using suprachoroidal administration

4/27/2021

Alkermes initiates ARTISTRY-6 trial of nemvaleukin alfa monotherapy in patients with melanoma

4/23/2021

Effects of Keytruda sustained after 3.5 years in high-risk stage 3 cutaneous melanoma

4/20/2021

Kaiku Health is teaming up with Novartis on a new initiative to help monitor and manage melanoma

4/16/2021

IDEAYA reports clinical data from the ongoing phase 1/2 trial evaluating darovasertib monotherapy and binimetnib combination therapy in patients with solid tumors, including metastatic uveal melanoma and skin melanoma

4/14/2021

Morphogenesis has received Fast-Track Designation for its skin cancer vaccination for advanced cutaneous melanoma from the FDA

4/13/2021

The AACR’s Presidential Address, Fighting Melanoma with the Immune System, discussed how researchers are working to change the treatment paradigm for patients with melanoma through next-generation techniques that stimulate immune response and amplify antitumor activity

4/12/2021

Instil Bio presents clinical data in metastatic melanoma in a late-breaking e-poster at the 2021 AACR annual meeting

4/11/2021

Combination of nivolumab and ipilimumab therapy in adjuvant setting failed to improve relapse-free survival for resected melanoma over nivolumab alone, according to CheckMate 915 trial

4/11/2021

Lifileucel yields durable responses in pretreated advanced melanoma

4/11/2021

Tebentafusp improves overall survival in advanced uveal melanoma

4/10/2021

Unselected autologous tumor infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma

4/10/2021

Immunotherapy response prediction using tumor mutational burden may differ between men and women with melanoma

4/10/2021

Initial treatment with tebentafusp shows significant OS improvement in metastatic uveal melanoma

4/9/2021

Case report describes myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis

4/9/2021

A cost-effective model for predicting a genetic risk for melanoma is receiving international endorsements

4/8/2021

Study reports that lumican inhibits in vivo melanoma metastasis by altering matrix-effectors and invadopodia markers

4/3/2021

A case report highlights atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors

4/1/2021

Phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma finds talimogene laherparepvec upregulates immune-cell populations in non-injected lesions

3/31/2021

Study links high levels of testosterone to increased risk of melanoma

3/30/2021

Huyabio International announces Phase 3 global clinical trial collaboration with Bristol Myers Squibb for subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy

3/30/2021

Quibim works with Highlight Therapeutics to improve immunotherapy in melanoma with AI

3/25/2021

Bristol Myers Squibb announces RELATIVITY-047, a trial evaluating Anti-LAG-3 antibody relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma

3/25/2021

Chronic immune-related adverse events appeared more common than previously thought after adjuvant anti-PD-1 immunotherapy for stage III to stage IV melanoma according to study published in JAMA Oncology

3/23/2021

IDEAYA Biosciences announces dose expansion of ongoing Phase 1/2 study evaluating IDE196 and binimetinib combination for metastatic uveal melanoma

3/17/2021

Structured Surveillance Program may provide earlier detection of melanoma

3/16/2021

New grant from Prevent Cancer Foundation will support further research on melanoma prevention and screening, as well as an exploration of genetic markers and quantifiable sun damage measures in risk assessment

3/12/2021

FDA’s Orphan Drug Status granted to nemvaleukin for mucosal melanoma

3/11/2021

Dermatology Physician Assistant Megan Thomas shares innovative technology for easy melanoma detection

3/11/2021

Alkermes announced that the company’s engineered interleukin-2 (IL-2) variant immunotherapy has been granted Orphan Drug Designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration (FDA)

3/10/2021

FDA’s Orphan Drug Status granted to LNS8801 for metastatic uveal melanoma

3/8/2021

Study finds that efficacy of anti-programmed cell death protein 1 therapy (anti-PD-1) differs by disease subtype among patients with metastatic acral and metastatic mucosal melanoma

3/8/2021

Seres Therapeutics has voluntarily discontinued further enrollment in the Melanoma Checkpoint and Gut Microbiome Alteration with Microbiome Intervention study evaluating SER-401 use for metastatic melanoma patients

3/5/2021

Baskin Lab at Cornell University has identified a pathway for effective drug treatment by regulating the protein PLEKHA4 in melanoma patients

3/2/2021

Highlight Therapeutics and Pivotal begin phase IIa melanoma trial to examine the administration of BO-112 in combination with an anti-PD1 in unresectable or metastatic melanoma patients

3/1/2021

Researchers at Columbia and MIT created a new technique called Perturb-CITE-sequencing to identify previously unknown resistance mechanisms to immune checkpoint inhibitors in melanoma patients

2/26/2021

Neoantigen long peptide vaccines (NeoVax) show durable T-cell responses in patients with advanced melanoma 4 years after initial vaccination in phase I study

2/19/2021

Immunocore’s novel bispecific protein, tebentafusp, granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for uveal melanoma

2/17/2021

Phase 2 of neoadjuvant tavokinogene teleplasmid plus nivolumab study doses first patient with operable, locally or regionally advanced melanoma before surgery

2/16/2021

Research findings suggest that DNA fragments released by dying tumor cells may serve as an early indicator of treatment success in advanced metastatic melanoma

2/15/2021

Phase III trial results suggest dabrafenib plus trametinib treatment improves relapse-free survival time for patients with stage III melanoma

2/15/2021

SkylineDx announces research collaboration with Dutch cancer registry to investigate patients with early-stage melanoma at high risk of disease-related fatality

2/12/2021

Cross-sectional study of sex differences in psychosocial quality of life of long-term melanoma survivors reveals clear distinctions in quality of life by sex

2/10/2021

Video about immunotherapy treatment pre-surgery for melanoma

2/8/2021

Neoadjuvant therapy for Stage III patients reduced likelihood of melanoma recurrence after surgery

2/8/2021

Fecal Transplants Boost Immunotherapy Response in People with Advanced Melanoma

2/8/2021

Studies have demonstrated benefits of Tumor Infiltrating Lymphocyte therapy for metastatic melanoma

2/8/2021

External Ear Melanoma Case Studies

2/3/2021

Nanotechnology particle advancement for treatment of melanoma

1/13/2021

Istari wins orphan drug designation for melanoma therapy

1/11/2021

Ultraviolet radiation drives mutations in a subset of mucosal melanomas

1/11/2021

Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma

1/11/2021

Ultraviolet radiation causes rare type of eye cancer

1/9/2021

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

1/8/2021

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

12/10/2020

Improving Sentinel Node Positivity Risk Prediction in Patients With Melanoma

12/8/2020

Marital Status, Anatomic Location & Stage at Melanoma Diagnosis

12/7/2020

Iridociliary Melanoma

12/4/2020

Nivolumab demonstrates survival benefits in the adjuvant setting (indirect treatment comparison study presented at SITC)

12/2/2020

ONCOS-102 plus pembrolizumab induces responses in anti-PD1-refractory melanoma

11/13/2020

Bempegaldesleukin plus nivolumab shows durable benefit in metastatic melanoma (SITC 2020)

11/9/2020

90% accuracy in detecting melanoma: New non-invasive method

11/8/2020

Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma

11/6/2020

Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests

11/5/2020

Working It Out: Does Exercise Boost the Effectiveness of Melanoma Treatment?

11/3/2020

Studies Find Connection Between Age and Melanoma Treatment Resistance

10/19/2020

How Do Melanoma Comorbidities Affect Patient Treatment Preferences?

9/17/2020

ESMO 2020 Virtual Conference: Provectus’ oncolytic immunotherapy shows positive action mid-stage melanoma study

9/17/2020

Melanoma Stage III Survival Benefit Sustained at 5 Years With Adjuvant Dabrafenib/Trametinib

9/11/2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

9/10/2020

GEP shows poor prognostic ability in recurrent Stage I Melanoma

9/7/2020

Study Identifies Prognostic Factors from Anti-PD-1 Therapy Use in Advanced Melanoma

9/7/2020

Postmenopausal exogenous hormone therapy and Melanoma risk in women: A systematic review and time-response meta-analysis.

8/20/2020

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma

8/18/2020

New App Helps Clinicians Manage Checkpoint Inhibitor AEs

8/17/2020

Nivolumab plus ipilimumab, pembrolizumab may be most cost-effective in advanced melanoma

7/30/2020

FDA Approves Atezolizumab Targeted Therapy Triple Combo for BRAF V600 Unresectable or Metastatic Melanoma

7/8/2020

Study Finds Racial, Socioeconomic Disparities in Uveal Melanoma Treatment

6/27/2020

Zoom calls have led to a rise in people using lasers to remove freckles despite cancer risk

6/25/2020

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

6/9/2020

Dramatic Drop in Skin Cancer Referrals During COVID-19 Crisis

6/8/2020

Personalized treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits

6/6/2020

Dabrafenib/Trametinib Brings Remission-Free Survival Advantage to Melanoma Subset

6/4/2020

Liquid Biopsy Predicts Outcomes in Stage III Melanoma

6/3/2020

Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1

5/30/2020

Pembrolizumab Provides Durable RFS Benefit When Used in the Adjuvant Setting in Stage III Melanoma

5/30/2020

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

5/29/2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

5/28/2020

Early Data Show Cancer Progression Associated With Increased Risk of Death in Patients With COVID-19

4/28/2020

FDA Approves Every-6-Week Pembrolizumab Dosage

4/27/2020

Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen

4/27/2020

Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma

4/8/2020

Lifirafenib Active in Melanoma, Other Solid Tumors

3/31/2020

Skin Cancer Education & Research Foundation Launches New Website – A New Resource for the Fight Against Skin Caner

3/25/2020

Seattle Cancer Care Alliance, at the epicenter of the US epidemic, provides insights for cancer care during the evolving the COVID-19 crisis.

2/12/2020

Dealing with Coronavirus (COVID-19): Recommendations from the CDC

2/11/2020

ANGLE device shows promise in assessing melanoma patients

2/10/2020

Elios Therapeutics vaccine scores well in Phase IIb melanoma study

1/13/2020

Melanoma cells may develop new ‘skin’ to resist cancer treatments

1/13/2020

Influenza Vaccines Triggers Immune System Response in Tumors

1/8/2020

U.S. cancer death rate sees largest yearly drop

1/3/2020

Weight loss surgery reduces skin cancer risk

12/9/2019

Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

12/8/2019

Speeding Access To New And Innovative Cancer Treatments

11/20/2019

Opdivo/Yervoy combo for melanoma fails in key patient population

11/13/2019

Cases of melanoma are falling among young people in the United States, study says

11/7/2019

Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response

11/1/2019

5-year survival data positive for nivolumab-based regimens in advanced melanoma

11/1/2019

STING pathway may be key to tumor cell recognition by immune cells

10/29/2019

ASDS Steering committee develops evidence-based consensus on cSCC staging, workup, treatment

9/27/2019

First melanoma test identifies those at low risk of cancer spreading

9/26/2019

Boost in Survival Rates for Younger Patients With Melanoma Attributed to Immunotherapy Agents

9/26/2019

Can Mohs micrographic surgery actually improve outcomes in stage I melanoma?

9/3/2019

SkylineDx secures funding for melanoma diagnostic test

9/3/2019

Successful Melanoma Risk Prediction Model Includes Whole-Body Nevi, Solar Lentigines

8/29/2019

Improved Overall Survival of Melanoma of the Head and Neck Treated with Mohs Micrographic Surgery versus Wide Local Excision

8/22/2019

Anti-TNF therapy given concurrently with ICI therapy may be beneficial in patients with GI irAEs

8/16/2019

Numbers count in the genetics of moles and melanomas

8/14/2019

ICIs may trigger rare form of bullous pemphigoid

8/14/2019

Dabrafenib-trametinib combination confers durable survival benefit in BRAF-mutated metastatic melanoma

7/30/2019

Dermatologists can limit skin, hair, nail side effects from cancer therapy

7/27/2019

ctDNA Monitoring Is Important for BRAF-Mutant Melanoma

7/25/2019

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

7/25/2019

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

7/25/2019

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

7/24/2019

First Melanoma Patient Dosed with Syntrix’ SX-682 in Combo with Keytruda in Phase 1/2 Trial

7/12/2019

Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort

6/19/2019

Implementation of a Multidisciplinary Approach for Managing Immunotherapy-Related Toxicities

6/11/2019

Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases

6/4/2019

Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®

5/29/2019

Array Bio’s Braftovi + Mektovi shows survival benefit in late-stage melanoma study

5/15/2019

Time to first distant recurrence of advanced melanoma: a survival link?

5/14/2019

May is Melanoma Awareness Month

5/14/2019

DIC in patients with melanoma

5/14/2019

Nivolumab for metastatic uveal melanoma

4/15/2019

What to Do When Anti–PD-1 Therapy Fails in Patients With Melanoma

4/14/2019

New cancer therapies offer great hope, but there can be suprising complications

4/11/2019

In Refractory Melanoma, Immunotherapy plus HDAC Inhibitor Yields ‘Impressive Results’

4/11/2019

Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma

4/9/2019

Cancer: ‘Off-the-shelf’ stem cell treatment enters clinical trial

4/3/2019

Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma

4/2/2019

Probiotics, Poor Diet May Interfere with Cancer Immunotherapy

4/2/2019

Apexigen reports positive Phase Ib APX005M clinical trial data

3/29/2019

Predicting Responders to ICB Therapy in Advanced Melanoma

3/27/2019

Complete Lymphadenectomy in Melanoma: No OS Benefit Found

3/27/2019

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

3/25/2019

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

3/25/2019

Why immunotherapy is not effective for some patients with metastatic melanoma and kidney cancer

3/22/2019

The immunology and immunotherapy of melanoma

3/21/2019

Melanoma therapies and the skin

3/21/2019

‘Optimistic’ Longer-term Outcomes for Metastatic Melanoma

3/20/2019

TVEC for Advanced Melanoma Yields Stunning Results in 3-Center Study

3/14/2019

Marine bacteria offer new weapon against melanoma

3/8/2019

FDG PET/CT effectively monitors immunotherapy for melanoma patients

3/8/2019

Syndax hits pause on entinostat/PD-1 program after midstage failures

3/6/2019

Nuclear medicine imaging assesses melanoma patients’ response to immunotherapy

3/5/2019

Study identifies a cause of melanoma treatment resistance

3/4/2019

Early response to PD-1 blockades predicts melanoma outcomes

2/26/2019

One Dose of Pembrolizumab Before Melanoma Surgery Can Put Patients in Remission

2/25/2019

Exicure Announces Dosing of First Patient in Phase 1b/2 Immuno-oncology Trial

2/21/2019

BU professor finds potential new treatment for melanoma

2/21/2019

New algorithm calculates drug synergy: Initial tests involve melanoma, lung cancer

2/20/2019

Melanoma brain metastases are immunosuppressive with treatment-resistant metabolism

2/20/2019

Study finds melanoma brain metastases are immunosuppressive with treatment-resistant metabolism

2/11/2019

Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma

2/11/2019

Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100

2/7/2019

Immunotherapy appears better than chemotherapy for aggressive type of skin cancer

1/31/2019

Treating melanoma by turning off a common mutation

1/16/2019

AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial

1/9/2019

New clinical trial for melanoma patients

1/9/2019

Skin rash post target therapy may be a “cytokine storm”

1/9/2019

Incognito may be the way to go in melanoma fight

1/7/2019

AAD updates cutaneous melanoma guidelines

12/20/2018

Scientists advise caution in immunotherapy research

12/19/2018

New PD-1 Inhibitor Approved for Melanoma in China

12/18/2018

Researchers discover how MAPK translocation leads to drug resistance in melanoma

12/18/2018

Two ways cancer resists treatment are actually connected, with one activating the other

12/18/2018

Merck bags European okay for adjuvant Keytruda in melanoma

12/13/2018

Quantifying the Benefits of Precision Oncology

11/15/2018

Recipient of GSK Award for Research Excellence, Professor Georgina Long, leads clinical trial evaluating adjuvant immunotherapy for melanoma patient–one patient’s story.

11/6/2018

Rare Genetic Disorder Research Opens Door to Novel Melanoma Therapy

11/6/2018

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

11/5/2018

Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma

11/3/2018

Melanoma: New guidelines for treatment from the AAD

11/2/2018

Specific CD8 T Cell States May Indicate Response to Melanoma Therapy

11/1/2018

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i)

10/22/2018

Follow-up study shows melanoma patients receiving adjuvant dabrafenib plus trametinib experience longer-term relapse-free survival benefit

08/31/2018

Combination Therapy May Offer Alternative Treatment Option for Advanced Melanoma

08/24/2018

Researchers discover epigenetic reason for drug resistance in a deadly melanoma

08/24/2018

Researchers find new therapy to prevent drug resistance for melanoma patients

08/22/2018

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

08/16/2018

Retinoic acid may improve immune response against melanoma

08/15/2018

Alton Memorial to host skin cancer screening Aug. 28

08/13/2018

PD-1 blockade provides ‘dramatic advance’ for the treatment of advanced melanoma

08/08/2018

Is Radioimmunotherapy a Path Forward for Melanoma?

07/27/2018

Keytruda is first I-O drug cleared for melanoma in China

07/26/2018

Cancer cells destroyed with two antipsychotic drugs

07/26/2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

07/18/2018

Melanoma biomarkers predicting checkpoint blocker response

07/13/2018

Melanoma: Immunotherapy for brain metastases ‘doubles survival’

07/12/2018

Immunotherapy doubles survival rates for patients with melanoma brain metastases

07/11/2018

Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab

07/11/2018

Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma

05/19/2018

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

05/10/2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

05/01/2018

FDA Approves Adjuvant Combination Treatment For Resected Stage III Melanoma With BRAFV600 Mutations

04/14/2018

Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.

03/06/2018

Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

01/18/2018

Adjuvant Pembrolizumab Improves RFS in Melanoma

01/17/2018

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

12/20/2017

FDA Approves Adjuvant Opdivo for Melanoma Treatment

12/20/2017

FDA Approves Adjuvant Opdivo for Melanoma Treatment

12/19/2017

Melanoma Nursing Initiative Launches to Support Early Recognition and Management of Side Effects From Immunotherapy and Targeted Therapies

10/18/2017

Timing of Melanoma Diagnosis, Treatment Critical to Survival

10/16/2017

Insurance Determines Melanoma Surgery Decision: Study

10/06/2017

Amgen’s Imlygic doubles response rate when added to checkpoint therapy

09/11/2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

09/11/2017

ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma

09/11/2017

Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma

09/11/2017

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

09/11/2017

Health-related quality of life results from the phase III CheckMate 067 study.

09/11/2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

09/11/2017

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

09/08/2017

A meta-analysis of nevus-associated melanoma: Prevalence and practical implications

09/06/2017

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

09/06/2017

New Drug on the Fast Track for Melanoma Treatment

08/30/2017

Moles Not the Only Way to Spot Deadly Melanoma

07/24/2017

FDA Approves Ipilimumab for Pediatric Melanoma

07/07/2017

Cancer Breakthrough: Personalized Melanoma Vaccines ‘Safe and Effective’ in First Human Clinical Trials

07/05/2017

Some Respond to Nivolumab After Melanoma Progression

06/29/2017

Study Raises Concern Over Accuracy of Melanoma Diagnoses

06/09/2017

Tanning Bed Use Declining Among U.S. Adults

06/09/2017

Study: Common Surgical Treatment for Melanoma Does Not Improve Patients’ Overall Survival